146 related articles for article (PubMed ID: 37669850)
1. Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER.
Sadda S; Sarraf D; Khanani AM; Tadayoni R; Chang AA; Saffar I; Gedif K; Wong DT
Br J Ophthalmol; 2024 May; 108(6):852-858. PubMed ID: 37669850
[TBL] [Abstract][Full Text] [Related]
2. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
[TBL] [Abstract][Full Text] [Related]
3. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU; Singh RP; Koh A; Ogura Y; Weissgerber G; Gedif K; Jaffe GJ; Tadayoni R; Schmidt-Erfurth U; Holz FG
Ophthalmology; 2021 Jan; 128(1):89-99. PubMed ID: 32574761
[TBL] [Abstract][Full Text] [Related]
4. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.
Lally DR; Loewenstein A; Arnold JJ; Yang YC; Gedif K; Best C; Patel H; Tadayoni R; Heier JS
Eye (Lond); 2023 Apr; 37(6):1242-1248. PubMed ID: 35597816
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal Assessment of Ellipsoid Zone Integrity, Subretinal Hyperreflective Material, and Subretinal Pigment Epithelium Disease in Neovascular Age-Related Macular Degeneration.
Ehlers JP; Zahid R; Kaiser PK; Heier JS; Brown DM; Meng X; Reese J; Le TK; Lunasco L; Hu M; Srivastava SK
Ophthalmol Retina; 2021 Dec; 5(12):1204-1213. PubMed ID: 33640493
[TBL] [Abstract][Full Text] [Related]
7. EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Post Hoc Analysis of the HAWK and HARRIER Studies.
Dugel PU; Jhaveri CD; Chakravarthy U; Wykoff CC; Singh RP; Hamilton R; Weissgerber G; Mulyukov Z; Holz FG
Retina; 2022 Mar; 42(3):511-518. PubMed ID: 34923515
[TBL] [Abstract][Full Text] [Related]
8. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
[TBL] [Abstract][Full Text] [Related]
9. PIGMENT EPITHELIAL DETACHMENT THICKNESS AND VARIABILITY AFFECTS VISUAL OUTCOMES IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Sarraf D; Khanani AM; Sadda SR; Chang A; Wong DT; Kempf AS; Saffar I; Tang S; Tadayoni R
Retina; 2024 Jan; 44(1):10-19. PubMed ID: 37824807
[TBL] [Abstract][Full Text] [Related]
10. Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid.
Singh RP; Jhaveri C; Wykoff CC; Gale RP; Staurenghi G; Iida T; Koh A; B G; Gedif K; Singer M
Ophthalmol Retina; 2022 May; 6(5):377-386. PubMed ID: 34968756
[TBL] [Abstract][Full Text] [Related]
11. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).
Wykoff CC; Brown DM; Maldonado ME; Croft DE
Br J Ophthalmol; 2014 Jul; 98(7):951-5. PubMed ID: 24518078
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.
Monés J; Biarnés M;
Eur J Ophthalmol; 2020 Sep; 30(5):1082-1090. PubMed ID: 31088111
[TBL] [Abstract][Full Text] [Related]
13. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
Monés J; Srivastava SK; Jaffe GJ; Tadayoni R; Albini TA; Kaiser PK; Holz FG; Korobelnik JF; Kim IK; Pruente C; Murray TG; Heier JS
Ophthalmology; 2021 Jul; 128(7):1050-1059. PubMed ID: 33207259
[TBL] [Abstract][Full Text] [Related]
14. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY; Haskova Z; Asik K; Baumal CR; Csaky KG; Eter N; Ives JA; Jaffe GJ; Korobelnik JF; Lin H; Murata T; Ruamviboonsuk P; Schlottmann PG; Seres AI; Silverman D; Sun X; Tang Y; Wells JA; Yoon YH; Wykoff CC;
Ophthalmology; 2024 Jun; 131(6):708-723. PubMed ID: 38158159
[TBL] [Abstract][Full Text] [Related]
15. Fluid Control in Neovascular Age-Related Macular Degeneration with Brolucizumab: An Analysis of the HAWK and HARRIER Phase 3 Trials.
Regillo C; Singh R; Hamilton R; Gedif K; Best C; Koh A; Holz FG
Ophthalmologica; 2022; 245(5):403-412. PubMed ID: 35468601
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.
Ogura Y; Jaffe GJ; Cheung CMG; Kokame GT; Iida T; Takahashi K; Lee WK; Chang AA; Monés J; D'Souza D; Weissgerber G; Gedif K; Koh A
Br J Ophthalmol; 2022 Jul; 106(7):994-999. PubMed ID: 34301613
[TBL] [Abstract][Full Text] [Related]
17. Association of Vascular Versus Avascular Subretinal Hyperreflective Material With Aflibercept Response in Age-related Macular Degeneration.
Kawashima Y; Hata M; Oishi A; Ooto S; Yamashiro K; Tamura H; Miyata M; Uji A; Ueda-Arakawa N; Tsujikawa A
Am J Ophthalmol; 2017 Sep; 181():61-70. PubMed ID: 28669776
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
Schmidt-Erfurth U; Kaiser PK; Korobelnik JF; Brown DM; Chong V; Nguyen QD; Ho AC; Ogura Y; Simader C; Jaffe GJ; Slakter JS; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Sowade O; Zeitz O; Norenberg C; Sandbrink R; Heier JS
Ophthalmology; 2014 Jan; 121(1):193-201. PubMed ID: 24084500
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the Efficacy of Brolucizumab with Natural Disease Progression in Wet AMD Using Clinical Data from the Phase III HAWK and HARRIER Trials and Modelled Placebo Data.
Agostini H; Mulyukov Z; Tsilimbaris M; Calvo P; Bucher F; Gaucher D; Pigeolet E; Colafrancesco V; Clemens A
Curr Eye Res; 2020 Oct; 45(10):1298-1301. PubMed ID: 32065533
[No Abstract] [Full Text] [Related]
20. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
Nguyen QD; Das A; Do DV; Dugel PU; Gomes A; Holz FG; Koh A; Pan CK; Sepah YJ; Patel N; MacLeod H; Maurer P
Ophthalmology; 2020 Jul; 127(7):963-976. PubMed ID: 32107066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]